The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice

Journal of Endocrinology 214(3):381–387, 2012

Benefit from our extensive know-how in NASH and test your compound in our validated DIO NASH mouse models.

Kidney

Check out our novel rodent models of diabetic nephropathy.

3D Imaging

Use quantitative light-sheet fluoresence microscopy to validate pre-clinical endpoints.

Obesity

Tap into our vast scientific experience with diet-induced obesity (DIO) models and other commercially available models.

Check out our novel rodent models of cardiovascular disease.

Brain

Check out our capabilities in neurodegenerative diseases.

Diabetes

Qualify and advance your assessment of novel compounds to treat type 2 diabetes and diabetic complications.

Lung (IPF)

Check out our services within lung diseases.